FAKTOR OPTIONSSCHEIN - NOVO-NORDISK B | Delayed Deutsche Boerse AG 05:50:54 03/06/2024 pm IST | ||
| 1,486 EUR | -15.35% |
|
| 1 month | -3.66% | ||
| 3 months | +33.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 1,486 | -15.35% |
| 31/24/31 | 1,755 | +7.19% |
| 30/24/30 | 1,637 | +13.69% |
| 29/24/29 | 1,440 | -4.88% |
| 28/24/28 | 1,514 | -7.53% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 05:50 pm IST
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PN10NV |
| ISIN | DE000PN10NV4 |
| Date issued | 03/10/2022 |
| Strike | 927.3 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 100 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3,064 € |
|---|---|
| Lowest since issue | 90.26 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
